Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patients

Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):252-258. doi: 10.1016/j.hemonc.2017.05.015. Epub 2017 Jun 15.

Abstract

Acute lymphoblastic leukemia (ALL) consists of precursor B ALL or T ALL phenotypes. In the pediatric population, ALL patients enjoy an 80% long-term survival with the current pediatric chemotherapy protocols as compared with 50% long-term survival in the adult population. In adults, complete remission rates are similar to those of pediatric patients; however, long-term survival is much lower with the majority of deaths attributable to relapsed disease. Postremission consolidation strategies in adults include chemotherapy, autologous, or allogeneic transplant. Pediatric-inspired chemotherapy protocols are being explored as a consolidation modality in adults. Assigning patients to either modality depends on patient and disease characteristics. Here, we review the literature on the use of hematopoietic cell transplantation as a consolidation modality in the treatment of adult ALL.

Keywords: Adult acute lymphoblastic leukemia; Allogeneic hematopoietic cell transplantation.

Publication types

  • Review

MeSH terms

  • Adult
  • Allografts
  • Autografts
  • Disease-Free Survival
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Survival Rate